Notícias e Atividades da Sangamo Therapeutics

Sangamo Therapeutics é uma empresa listada sob o símbolo SGMO (US).

Veja o organograma con seus 22 executivos principais

Biografias mais buscadas da Sangamo Therapeutics

• Sandy Macrae, Director, President and Chief Executive Officer
• Karen Smith, Director
• Courtney Beers, Director

Criar um alerta
para seguir os movimentos de executivos da Sangamo Therapeutics.

Sangamo Therapeutics possui 1.919 concorrentes concorrentes Sanofi (França), Moderna (Estados Unidos) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• Agenus acaba de anunciar uma arrecadação de fundos de 340 milhões de dólares. (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).

Outros contatos sugeridos na indústria do Farmacêutica

• David Ricks - President, Chief Executive Officer and Chairman of the Board da Eli Lilly
• Joaquin Duato - Chief Executive Officer and Chairman of the Board da Johnson & Johnson
• Richard Saynor - Chief Executive Officer da Sandoz

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Sangamo Therapeutics

• Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast | Sangamo Therapeutics, Inc.
• European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation | Sangamo Therapeutics, Inc.
• News Releases | Sangamo Therapeutics, Inc.
• News Releases | Sangamo Therapeutics, Inc.
• Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences | Sangamo Therapeutics, Inc.
• Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results | Sangamo Therapeutics, Inc.
• Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) | Sangamo Therapeutics, Inc.
• Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast | Sangamo Therapeutics, Inc.
• News Releases | Investor Relations | Sangamo Therapeutics, Inc.
• Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment | Sangamo Therapeutics, Inc.
• View more press releases Close

Redes sociais sobre Sangamo Therapeutics

• Sangamo Therapeutics na Wikipedia, Google News e Yahoo Finance
• Sangamo Therapeutics na LinkedIn, X (Twitter) e YouTube